Floatz logo

EXEMESTANE

Her2-Receptor Negative Breast Cancer

National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

185 Active assets in the Her2-Receptor Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Durvalumab
National Cancer Institute (NCI)
Phase 3BB
Capecitabine
Kristina A. Fanucci
Phase 4BB

View all 50 →

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerActive
BBB
Indicative · Phase 4
75 / 100
View asset →
hormone receptor-positive breast cancerActive
BBB
Indicative · Phase 4
75 / 100
View asset →
breast carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →